Anti‑allergic action of bacillus Calmette‑Guerin extract in experimental mast cell‑mediated anaphylactic models

Sun,Mingli; Wang,Yong; Zhao,Haishan; Yao,Weifan; Yu,Xiaosong

doi:10.3892/mmr.2017.7383

Anti‑allergic action of bacillus Calmette‑Guerin extract in experimental mast cell‑mediated anaphylactic models

Authors:
- Mingli Sun
- Yong Wang
- Haishan Zhao
- Weifan Yao
- Xiaosong Yu
View Affiliations

Affiliations: Department of Pharmacology, School of Pharmacy, China Medical University, Shenyang, Liaoning 110122, P.R. China, Department of General Practice, The First Hospital of China Medical University, Shenyang, Liaoning 110001, P.R. China
Published online on: August 29, 2017 https://doi.org/10.3892/mmr.2017.7383
Pages: 6248-6254

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Allergy is an acquired hypersensitivity reaction of the immune system mediated by IgE‑induced mast cell degranulation. In China, bacillus Calmette‑Guerin extract (BCGE) has been shown to be clinically effective for regulating immunity, which enhances the resistance of the body to anaphylactic disease, infectious diseases and cancer. However, the mechanisms remain to be fully elucidated. The present study investigated the potential anti‑allergic effects of BCGE in animal models of mast cell‑dependent anaphylaxis and mechanisms of BCGE in mast cells. Anti‑allergic actions of BCGE were evaluated in passive cutaneous anaphylaxis, dextran T40‑induced scratching behavior mouse models, and in ovalbumin (OVA)‑induced contraction of intestinal tube isolated from OVA‑sensitized guinea pigs. Direct mast cell‑stabilizing effects of BCGE were examined in mast cells from the abdominal cavity of OVA‑sensitized rats. Anti‑allergic signaling mechanisms of BCGE in mast cells were investigated by detection of cyclic adenosine monophosphate levels and protein kinase A expression in mast cells. It was observed that BCGE prevented OVA‑induced cutaneous vascular hyperpermeability, skin itching, elevation in plasma histamine levels and abdominal cavity fluid mast cell degranulation in animal models, in a dose‑dependent manner. BCGE also suppressed OVA‑mediated guinea pig intestinal tube contraction in vitro. In addition, BCGE was found to increase the levels of interferon‑γ, and reduce the levels of interleukin‑4 and OVA‑sIg E levels in OVA‑sensitized rats. BCGE also increased levels of cyclic adenosine monophosphate and the expression of protein kinase A in mast cells separated from the abdominal cavity fluid of OVA‑sensitized rats. In conclusion, the results suggested that BCGE possesses anti‑allergic activity by inhibiting IgE‑induced mast cell degranulation, providing a foundation for the development of BCGE for the treatment of mast cell‑mediated allergic disorders.

View Figures

View References

1	Galli SJ, Tsai M and Piliponsky AM: The development of allergic inflammation. Nature. 454:445–454. 2008. View Article : Google Scholar : PubMed/NCBI
2	Simons FE: Anaphylaxis. J Allergy Clin Immunol. 125 2 Suppl 2:S161–S181. 2010. View Article : Google Scholar : PubMed/NCBI
3	Choi EJ, Lee S, Hwang JS, Im SH, Jun CD, Lee HS and Kim SH: DA-9601 suppresses 2, 4-dinitrochlorobenzene and dust mite extract-induced atopic dermatitis-like skin lesions. Int Immunopharmacol. 11:1260–1264. 2011. View Article : Google Scholar : PubMed/NCBI
4	Furue M, Terao H, Rikihisa W, Urabe K, Kinukawa N, Nose Y and Koga T: Clinical dose and adverse effects of topical steroids in daily management of atopic dermatitis. Br J Dermatol. 148:128–133. 2003. View Article : Google Scholar : PubMed/NCBI
5	Leung DY, Jain N and Leo HL: New concepts in the pathogenesis of atopic dermatitis. Curr Opin Immunol. 15:634–638. 2003. View Article : Google Scholar : PubMed/NCBI
6	Galli SJ, Nakae S and Tsai M: Mast cells in the development of adaptive immune responses. Nat Immunol. 6:135–142. 2005. View Article : Google Scholar : PubMed/NCBI
7	Caramalho I, Lopes-Carvalho T, Ostler D, Zelenay S, Haury M and Demengeot J: Regulatory T cells selectively express toll-like receptors and are activated by lipopolysaccharide. J Exp Med. 197:403–411. 2003. View Article : Google Scholar : PubMed/NCBI
8	Yamamoto S, Kuramoto E, Shimada S and Tokunaga T: In vitro augmentation of natural killer cell activity and production of interferon-alpha/beta and -gamma with deoxyribonucleic acid fraction from Mycobacterium bovis BCG. Jpn J Cancer Res. 79:866–873. 1988. View Article : Google Scholar : PubMed/NCBI
9	Yamamoto S, Yamamoto T, Kataoka T, Kuramoto E, Yano O and Tokunaga T: Unique palindromic sequences in synthetic oligonucleotides are required to induce IFN [correction of INF] and augment IFN-mediated [correction of INF] natural killer activity. J Immunol. 148:4072–4076. 1992.PubMed/NCBI
10	Fujieda S, Iho S, Kimura Y, Sunaga H, Igawa H, Sugimoto C, Yamamoto S and Saito H: DNA from mycobacterium bovis bacillus Calmette-Guérin (MY-1) inhibits immunoglobulin E production by human lymphocytes. Am J Respir Crit Care Med. 160:2056–2061. 1999. View Article : Google Scholar : PubMed/NCBI
11	Cheng D, Zheng B, Chen W and Chen Z: The prophylactic effect of BCG polysaccharides nucleic acid on the acute attack of chronic obstructive pulmonary disease. Hua Xi Yi Ke Da Xue Xue Bao. 33:121–122. 2002.(In Chinese). PubMed/NCBI
12	Xiong C, Li Q, Lin M, Li X, Meng W, Wu Y, Zeng X, Zhou H and Zhou G: The efficacy of topical intralesional BCG-PSN injection in the treatment of erosive oral lichen planus: A randomized controlled trial. J Oral Pathol Med. 38:551–558. 2009. View Article : Google Scholar : PubMed/NCBI
13	Deng T, Liu B, Duan X, Zhang T, Cai C and Zeng G: Systematic review and cumulative analysis of the combination of mitomycin C plus Bacillus Calmette-Guérin (BCG) for non-muscle-invasive bladder cancer. Sci Rep. 7:31722017. View Article : Google Scholar : PubMed/NCBI
14	Jin YJ, Song ZY, Hu Y, Qian XB, Wang XY and He XY: Effects of montelukast and BCG-PSN on the expression of STAT5b mRNA and IL-4 mRNA in blood mononuclearcells of rats with asthma. Zhongguo Dang Dai Er Ke Za Zhi. 11:133–137. 2009.(In Chinese). PubMed/NCBI
15	Zuo CX, Huang JH, Liao ZH, Lu JY and Chen J: Effects of BCG-PSN on serum levels of IL-4 and IL-12 in patients with condyloma acuminatum. Zhong Nan Da Xue Xue Bao Yi Xue Ban. 29:690–692. 2004.(In Chinese). PubMed/NCBI
16	Sun M, Wang S, Zhao L, Zhao H, Yao W, Jin W and Wei M: Suppression of 2,4-dinitrochlorobenzene-induced atopic dermatitis by extract of Bacillus Calmette-Guerin. Mol Med Rep. 9:689–694. 2014.PubMed/NCBI
17	Cho A and Seok SH: Ethical guidelines for use of experimental animals in biomedical research. J Bacteriol Virol. 43:18–26. 2013. View Article : Google Scholar
18	Finkelman FD: Anaphylaxis: Lessons from mouse models. J Allergy Clin Immunol. 120:506–515; quiz 516–517. 2007. View Article : Google Scholar : PubMed/NCBI
19	Inagaki N and Nagai H: Analysis of the mechanism for the development of allergic skin inflammation and the application for its treatment: Mouse models for the development of remedies for human allergic dermatitis. J Pharmacol Sci. 110:251–259. 2009. View Article : Google Scholar : PubMed/NCBI
20	Evora PR and Simon MR: Role of nitric oxide production in anaphylaxis and its relevance for the treatment of anaphylactic hypotension with methylene blue. Ann Allergy Asthma Immunol. 99:306–313. 2007. View Article : Google Scholar : PubMed/NCBI
21	Kumar P, Shen Q, Pivetti CD, Lee ES, Wu MH and Yuan SY: Molecular mechanisms of endothelial hyperpermeability: Implications in inflammation. Expert Rev Mol Med. 11:e192009. View Article : Google Scholar : PubMed/NCBI
22	Matsuoka H, Maki N, Yoshida S, Arai M, Wang J, Oikawa Y, Ikeda T, Hirota N, Nakagawa H and Ishii A: A mouse model of the atopic eczema/dermatitis syndrome by repeated application of a crude extract of house-dust mite Dermatophagoides farinae. Allergy. 58:139–145. 2003. View Article : Google Scholar : PubMed/NCBI
23	Kim SH, Jun CD, Suk K, Choi BJ, Lim H, Park S, Lee SH, Shin HY, Kim DK and Shin TY: Gallic acid inhibits histamine release and pro-inflammatory cytokine production in mast cells. Toxicol Sci. 91:123–131. 2006. View Article : Google Scholar : PubMed/NCBI
24	Kang JS, Yoon WK, Han MH, Lee H, Lee CW, Lee KH, Han SB, Lee K, Yang KH, Park SK and Kim HM: Inhibition of atopic dermatitis by topical application of silymarin in NC/Nga mice. Int Immunopharmacol. 8:1475–1480. 2008. View Article : Google Scholar : PubMed/NCBI
25	Sullivan TJ, Parker KL, Kulczycki A Jr and Parker CW: Modulation of cyclic AMP in purified rat mast cells. III. Studies on the effects of concanavalin A and anti-IgE on cyclic AMP concentrations during histamine release. J Immunol. 117:713–716. 1976.PubMed/NCBI
26	Kurosawa M, Mori H, Nagai H and Koda A: Change in the activity of the cyclic AMP-dependent protein kinase in antigen-stimulated sensitized mast cells and effect of drugs inhibiting allergic mediator release. Jpn J Pharmacol. 43:454–457. 1987. View Article : Google Scholar : PubMed/NCBI
27	Kurosawa M: Studies of phosphorylation in rat mast cells (sixth report). Cyclic AMP-dependent protein phosphorylation in rat mast cell granule membranes. Nihon Yakurigaku Zasshi. 86:87–92. 1985.(In Japanese). View Article : Google Scholar : PubMed/NCBI
28	Sullivan TJ, Parker KL, Eisen SA and Parker CW: Modulation of cyclic AMP in purified rat mast cells. II. Studies on the relationship between intracellular cyclic AMP concentrations and histamine release. J Immunol. 114:1480–1485. 1975.PubMed/NCBI
29	Lau HY and Chan CL: Modulation of intracellular cyclic AMP in immunologically activated rat peritoneal mast cells by prostaglandin D2. Inflamm Res. 50 Suppl 2:S61–S62. 2001.PubMed/NCBI